Massey brings lesson plans to life
VCU Massey Cancer Center's Goodwin Research Laboratory recently served as a real-world classroom for local high school students learning about cancer research. Two dozen freshman biology students from Henrico High School's International Baccalaureate program were given a rare first-hand look at cancer cells and research labs and the unique opportunity to interact with some of the country's top research scientists.
Researchers uncover new mechanism in multiple myeloma cells
Researchers at Virginia Commonwealth University Massey Cancer Center have discovered a mechanism in multiple myeloma cells that plays a critical role in the cells’ ability to resist treatments involving a class of drugs known as histone deacetylase inhibitors (HDACIs). The findings could lead to more effective treatments for multiple myeloma, leukemia and other malignant blood disorders.
Lab research suggests clinical trial may be especially effective against rare mantle cell lymphoma
A multi-institutional Phase I clinical trial testing the effects of a new combination of chemotherapies on rare forms of lymphoma is poised to begin at Virginia Commonwealth University Massey Cancer Center. As the trial prepares to open, new laboratory research from Massey scientists suggests that the novel therapy may warrant particular attention in patients with mantle cell lymphoma (MCL), a relatively rare form of non-Hodgkin’s lymphoma.
Researcher Steven Grant assumes prestigious roles at the National Cancer Institute
World renown for his development of novel drug combinations to treat blood cancers, VCU Massey Cancer Center researcher Steven Grant, M.D., has been asked to serve the National Cancer Institute (NCI) as a member of their Investigational Drug Steering Committee (IDSC) and as IDSC Lymphoma Expert and Liaison to the Lymphoma Steering Committee (LYSC).
Scientists defeat hurdle to eradicating inactive multiple myeloma cells
Researchers at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that delivers a deadly one-two blow to kill even the most inactive, or cytokinetically quiescent, cells. Because multiple myeloma can rest in a non-proliferative state for extended periods of time, this discovery may help to overcome a major hurdle to treating this fatal disease.